Home/ Stocks/ INMB

INmune Bio Inc. Common stock

INMB XNAS

$2.08 +0.12 (+6.04%) ▲ 15-min delayed

Open

$1.97

High

$2.10

Low

$1.92

Volume

952.8K

Market Cap

$50.78M

About INmune Bio Inc. Common stock

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 21 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-5,407,000	$-0.20
FY 2025	$50.0K	$-45,933,000	$-1.86
Q3 2025	$0	$-6,472,000	$-0.24
Q2 2025	$0	$-24,458,000	$-1.05

Related Market News

No specific coverage for INMB yet. Check out our latest market news or earnings calendar.

Get INMB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on INmune Bio Inc. Common stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.